- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04892030
Evaluating a Remotely Delivered Plant-Based Behavioral Weight Loss Treatment
June 29, 2021 updated by: Evan Forman, Drexel University
A Pilot Study of a Novel Ad Libitum Plant-Based Behavioral Weight Loss Treatment
Many individuals do not achieve clinically significant weight loss following traditional lifestyle modification interventions, potentially because weight loss is dependent upon calorie tracking compliance (to achieve calorie prescriptions), which decreases over time for most.
By contrast, non-energy-restricted whole food plant-based diets (WFPBD) have been demonstrated to promote clinically significant weight loss even without calorie prescriptions.
The present pilot trial represents the first, to the knowledge of our study team, to empirically test a remotely delivered WFPBD behavioral weight loss intervention for adults with overweight or obesity.
Over 12-weeks, participants (N = 21) will follow a non-energy-restricted WFPBD and received nutritional counseling and behavioral weight loss intervention.
Participation will occur in two phases (Phase 1: n = 7; Phase 2: n = 14), between which iterative changes to the intervention will be made.
Assessments will occur at baseline, mid-treatment, post-treatment, and 3-month follow-up.
Data will be analyzed using an intent-to-treat approach.
The primary aims of the study will be to assess retention feasibility and acceptability.
The secondary aims will be to evaluate the preliminary effectiveness of the intervention on: (1) percent weight loss; (2) dietary intake (i.e., increased intake of low-fat plant-based whole foods and decreased in intake of processed foods and animal products); and (3) waist circumference.
The exploratory aims will be to evaluate the preliminary effectiveness of the intervention on physical- and mental health-related quality of life, and to examine potential moderators of treatment success (plant-based diet history, internal disinhibition, social support vs. social sabotage, self-compassion, and psychological flexibility).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Weight Eating and Lifestyle Science Center, Drexel University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 18-75
- Current BMI ≥ 25 kg/m2
- Reporting a desire to lose weight
- Have at-home internet access
- Proficiency in speaking, reading, and writing English
- Willing to consume a whole foods plant-based diet for the study duration
Exclusion Criteria:
- Use of medications for weight loss
- Recent weight loss (≥5% weight loss in prior 3-months)
- Current or planned pregnancy within the study period
- History of bariatric surgery
- Currently following a low-fat plant-based diet
- Diagnosis of a serious medical condition influencing weight, appetite, or eating behavior
- Diagnosis of a serious psychiatric condition that may influence weight, appetite, or eating behavior
- Current substance use disorder
- Participation in a concurrent weight loss program
- Planning on quitting smoking over the intervention period (if current smoker)
- Eating pathology (lifetime history of an eating disorder, ≥ 9 binge eating episodes in the past 3 months, or > 5 compensatory episodes in the past 3 months)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intervention
All participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies remotely, through an e-learning platform.
|
Over the course of 12-weeks, participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies through an e-learning platform.
Each week, participants will also complete a 15-minute coaching call to provide positive reinforcement and problem-solving support.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retention feasibility as assessed by the number of participants successfully retained in the intervention
Time Frame: Week 12 (post-intervention)
|
The number of participants who are retained in the study, as defined by completing the post-treatment assessment and at least 10 out of 12 of the weekly intervention modules.
Successful retention will be defined as at least 80% of participants being retained in the study.
|
Week 12 (post-intervention)
|
Acceptability as assessed by self-reported acceptability of the intervention
Time Frame: Week 12 (post-intervention)
|
Acceptability will be assessed with three items, in which participants will report the degree to which they were satisfied with the intervention, found the intervention to be helpful, and the likelihood that they would recommend it to family/friends on a Likert scale ranging from 1 (Not at all) to 5 (Very much).
|
Week 12 (post-intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preliminary effectiveness of the intervention on weight loss, as assessed by self-reported weight from baseline to post-intervention
Time Frame: Measured once weekly from Week 0 (baseline) to Week 12 (post-intervention), and at 3-month follow-up
|
Weight loss will be self-reported by participants weekly, and at baseline, mid-treatment, post-treatment, and 3-month follow-up.
To evaluate the preliminary effectiveness of the intervention on weight loss, percent weight change from baseline to post-intervention will be evaluated.
Preliminary weight loss effectiveness will be defined as at least 50% of participants losing at least 5% of their initial body weight by post-treatment.
|
Measured once weekly from Week 0 (baseline) to Week 12 (post-intervention), and at 3-month follow-up
|
Preliminary effectiveness of the intervention on dietary intake, as assessed by self-reported dietary intake from baseline to post-intervention
Time Frame: Week 0 (baseline), Week 6 (mid-treatment), Week 12 (post-intervention), and 3-month follow-up
|
Dietary intake will be assessed using a food frequency questionnaire tailored to examine adherence to the prescribed intervention (whole food plant-based) diet.
A dietary adherence index ranging from 0 (no adherence) to 100 (complete adherence) will be created, and preliminary dietary change effectiveness will be defined as at least 80% of participants improved their dietary adherence score by at least 20% by post-treatment.
|
Week 0 (baseline), Week 6 (mid-treatment), Week 12 (post-intervention), and 3-month follow-up
|
Preliminary effectiveness of the intervention on waist circumference, as assessed by self-reported waist circumference from baseline to post-intervention
Time Frame: Week 0 (baseline), Week 6 (mid-treatment), Week 12 (post-intervention), and 3-month follow-up
|
Waist circumference will be self-reported by participants weekly, and at baseline, mid-treatment, post-treatment, and 3-month follow-up.
To evaluate the preliminary effectiveness of the intervention on waist circumference, waist circumference change from baseline to post-intervention will be examined.
Preliminary weight loss effectiveness will be defined as at least 50% of participants losing at least 5% of their initial waist circumference by post-treatment.
|
Week 0 (baseline), Week 6 (mid-treatment), Week 12 (post-intervention), and 3-month follow-up
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preliminary effectiveness of the intervention on quality of life, as assessed by self-reported quality of life from baseline to post-intervention
Time Frame: Week 0 (baseline), Week 6 (mid-treatment), Week 12 (post-intervention), and 3-month follow-up
|
Quality of life will be assessed using the 36-item Short-Form General Health Survey (SF-36).
The SF-36 assesses eight domains: physical functioning, limits due to physical health, pain, general health, energy/fatigue, social functioning, emotional wellbeing, and mental health.
Scores in each domain are converted to a scale from 0 to 100, with higher scores indicating better functioning in each domain.
This scale produces both physical and mental health component summaries, both of which will be examined.
A reliable change index at the .20 level will be calculated for both the physical- and mental- health-related component scores.
If the product exceeds a z-score of 1.282 at post-treatment, reflecting 80% confidence, then results will be defined as suggestive of preliminary quality of life effectiveness.
|
Week 0 (baseline), Week 6 (mid-treatment), Week 12 (post-intervention), and 3-month follow-up
|
Association between plant-based diet history at Week 0 (baseline) and percent weight loss at Week 12 (post-treatment)
Time Frame: Week 0 (baseline) and Week 12 (post-treatment)
|
To assess plant-based diet history, a plant-based diet familiarity score will be computed from participants' self-reported familiarity with plant-based diets, reported on a scale ranging from 0 (Not at all familiar) to 4 (Very familiar), and from reports of whether they have eaten a plant-based diet in the past, for at least 3-months.
Participants will be given 4 points if previously vegan, 3 if previously vegetarian, 2 if previously pescatarian or 1 if previously semi-vegetarian ("flexitarian").
These scores will be added to self-reported plant-based diet familiarity, resulting in a "plant-based diet familiarity" score that could range from 0 to 7. To evaluate the potential moderating effect of plant-based diet history on weight loss outcomes, the correlation between plant-based diet history and post-treatment percent weight loss will be examined.
|
Week 0 (baseline) and Week 12 (post-treatment)
|
Association between social support vs. social sabotage at Week 6 (mid-treatment) and percent weight loss at Week 12 (post-treatment)
Time Frame: Week 6 (mid-treatment) and Week 12 (post-treatment)
|
To assess social support vs. social sabotage, participants will complete the Social Support and Sabotage Scale from Ball & Crawford (2006).
On this measure, participants separately rate the degree to which friends and family act in ways that support or hinder their healthy eating efforts with a Likert scale ranging from 1 (Almost never) to 5 (Almost always).
Scores will be averaged for each subscale to compute: 1) support for health behaviors from friends, 2) support for health behaviors from family, 3) sabotage for health behaviors from friends, and 4) sabotage for health behaviors from family.
To evaluate the potential moderating effect of social support vs. social sabotage on weight loss outcomes, the correlations between social support vs. social sabotage for health behavior scores and post-treatment percent weight loss will be examined.
|
Week 6 (mid-treatment) and Week 12 (post-treatment)
|
Association between internal disinhibition at Week 0 (baseline) and percent weight loss at Week 12 (post-treatment)
Time Frame: Week 0 (baseline) and Week 12 (post-treatment)
|
To assess internal disinhibition, participants will complete the disinhibition subscale from the Mindful Eating Questionnaire (MEQ; Framson et al., 2009).
Responses are on a Likert scale ranging from 1 (Never/Rarely) to 4 (Usually/Always).
Scores for each item are averaged to compute an overall disinhibition score.
To evaluate the potential moderating effect of internal disinhibition on weight loss outcomes, the correlation between internal disinhibition and post-treatment percent weight loss will be examined.
|
Week 0 (baseline) and Week 12 (post-treatment)
|
Association between self-compassion at Week 0 (baseline) and percent weight loss at Week 12 (post-treatment)
Time Frame: Week 0 (baseline) and Week 12 (post-treatment)
|
To assess self-compassion, participants will complete the Self-Compassion Scale-Short Form, which assess how participants generally treat themselves during difficult times.
Responses are on a Likert scale ranging from 1 (Almost never) to 5 (Almost always).
Scores for each item are averaged to compute an overall self-compassion score.
To evaluate the potential moderating effect of self-compassion on weight loss outcomes, the correlation between self-compassion and post-treatment percent weight loss will be examined.
|
Week 0 (baseline) and Week 12 (post-treatment)
|
Association between psychological flexibility at Week 6 (mid-treatment) and percent weight loss at Week 12 (post-treatment)
Time Frame: Week 6 (mid-treatment) and Week 12 (post-treatment)
|
To assess psychological flexibility, participants will complete the personalized psychological flexibility index, which assesses the ability to pursue valued life aims despite the presence of distress.
Responses are on a Likert scale ranging from 1 (Strongly Disagree) to 7 (Strongly Agree).
Scores for each item are averaged to compute an overall psychological flexibility score.
To evaluate the potential moderating effect of psychological flexibility on weight loss outcomes, the correlation between psychological flexibility and post-treatment percent weight loss will be examined.
|
Week 6 (mid-treatment) and Week 12 (post-treatment)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Evan M Forman, Ph.D., Drexel University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 25, 2020
Primary Completion (ACTUAL)
May 18, 2021
Study Completion (ACTUAL)
May 18, 2021
Study Registration Dates
First Submitted
May 6, 2021
First Submitted That Met QC Criteria
May 13, 2021
First Posted (ACTUAL)
May 19, 2021
Study Record Updates
Last Update Posted (ACTUAL)
July 1, 2021
Last Update Submitted That Met QC Criteria
June 29, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EATVEG838
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data will be shared in a public repository stripped of any identifying participant information.
IPD Sharing Time Frame
Immediately following manuscript publication, the study data study and statistical code used for analyses will be shared.
IPD Sharing Supporting Information Type
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Whole Food Plant-Based Behavioral Weight Loss Treatment
-
University of RochesterTerminatedProteinuria | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 4United States
-
University of California, San DiegoRecruitingChronic Lymphocytic Leukemia Stage A(0)United States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteCompletedDiet Modification | CardiologyUnited States
-
Drexel UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingObesity | Weight LossUnited States
-
Stanford UniversityCompletedDiet, HealthyUnited States
-
Drexel UniversityRecruitingObesity | Weight LossUnited States
-
The Miriam HospitalNational Heart, Lung, and Blood Institute (NHLBI)Unknown
-
The Miriam HospitalCompleted
-
Amsterdam University of Applied SciencesNot yet recruiting